Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BIA202204

IL10 / IL10RA mAb

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: IL10 / IL10RA mAb
    Indications: Immunodeficiencies
    Research phase: PCC
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.


    (1). Higher IL10 level in severe CRS, sepsis and HLH patients.
    (2). Blocking IL10/IL10R signaling pathway is a new strategy of treating CRS, HLS, and sepsis.


    lt is reported that a high ratio of lLl0 to TNFα correlated with mortality in patients (464 cases) with community-acquired infection.


    2. Sepsis: high mortality (19 million patients, the mortality rate >25%), huge market size ($ 3.2 billion in 2018, with a CAGR of 7.5%).


    3. Unique fully human mAb with low immunogenicity.


    4. ADCC and ADCP silenced lgG4 ensures antibody safety.


    5. Superior stability and good druggability.


    After 6 times of frozen-thawing or storage at 40°C for 4 weeks, the activity of the candidate did not change significantly.



    6. Both mAbs have blocking activity on lL10/IL10RA signal pathway, and the efficacy can be seen in the sepsis modeling mouse.




    Both mAbs have blocking activity on lL10/IL10RA signal pathway, and the efficacy can be seen in the sepsis modeling mouse.




    Both mAbs have blocking activity on lL10/IL10RA signal pathway, and the efficacy can be seen in the sepsis modeling mouse.

  • Project Introduction

    1. Asset type: IL10 / IL10RA mAb

    2. Indication: Sepsis/ HLH/ CRS

    3. Modality: fully human mAb, ADCC and ADCP silenced lgG4

    4. Research phase: Ready for CMC development

    5. Cooperation demands:   License-out or co-development

    6. Research progress:

    (1). IL10 / IL10RA mAb showed excellent stability and good druggability.

    (2). Ready for CMC development.

    (3). IL10 / IL10RA mAb significantly prolonged the survival of mice with LPS-induced sepsis (90 % vs 30 %).

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message